Drug Discovery Technologies
G. Binnig, Definiens (Munich, DE)
S. Kirchner, F. Hoffmann-La Roche Ltd. (Basel, CH)
G. Schmidt, Definiens (Munich, DE)
P. Baaske, NanoTemper Technologies GmbH (Munich, DE)
J. Knop, Amgen Research GmbH (Regensburg, DE)
S. Schwengberg, Axiogenesis AG (Cologne, DE)
L. Kaestner, Saarland University (Homburg, DE)
G. Dernick, F. Hoffmann-La Roche Ltd. (Basel, CH)
J. Kolb, Bristol-Myers Squibb, (Wallingford, US)
Y. Asai, ReproCell (Tokyo, Japan)
P. Shuck, National Institutes of Health (Bethesda, US)
R. Zenobi, ETH (Zurich, CH)
Biological Space: Target and Tools
J.P. Ley, Symrise GmbH & Co. KG (Holzminden, DE)
S. Damak, Nestlé Research Center (Lausanne, CH)
A. Schnieke, Technische Universität München (Freising-Weihenstephan, DE)
T.A. Bennett, Vivia Biotech (Madrid, ES)
D. Leroy, Medicine for Malaria Venture (Geneva, CH)
A. Bassoli, University of Milan (Milan, IT)
S.C. Desbordes, CRG-Centre de Regulació Genòmica (Barcelona, ES)
P. Hammann, Sanofi-Aventis (Hoechst, DE)
M. de los Frailes, GSK (Tres Cantos, ES)
D. Fabbro, Novartis Pharma AG (Basel, CH)
J. Kammonen, Pfizer (Sandwich, UK)
E. Alvarez, GSK (Tres Cantos, ES)
Chemical Space: Maximizing Compound Value
J. Harris, BioFocusDPI (Cambridge, UK)
T. Oprea, University of New Mexico (Albuquerque, US)
P. Ertl, Novartis Pharma AG (Basel, CH)
M.P. Gleeson, Kasetsart University (Bangkok, TH)
J. Loesel, Pfizer (Sandwich, UK)
C.G. Wermuth, Prestwick Chemical (Illkirch, FR)
J. Overrington, Wellcome Trust Genome Campus (Cambridge, UK)
T. Haubenreich, Science Information International Ltd. (Schwetzingen, DE)
J. Mestres, Pompeu Fabra University (Barcelona, ES)
Early Safety Evaluation
R. Callaghan, University of Oxford (Oxford, UK)
A. Reichel, Bayer Schering Pharma AG (Berlin, DE)
P. Äänismaa, Biozentrum der Univerität Basel (Basel, CH)
Pharmacodynamics / Biomarkers
T. Joos, NMI Natural and Medical Sciences Institute at the University of Tuebingen (Reutlingen, DE)
A. Hofmann, ETH (Zurich, CH)
M. Stocchero, S-IN Soluzioni Informatiche (Vicenza, IT)
I. L. Cima, ETH (Zurich, CH)
V. Libri, Imperial College (London, UK)
P. van der Graaf, Pfizer (Sandwich, UK)
Structural and Computational Drug Discovery
R. Hilgenfeld, University of Lubeck (Lubeck, DE)
B. Kramer, 4SC (Munich, DE)
J.F. Bazan, Genentech, Inc. (San Francisco, US)
M. Noble, University of Oxford (Oxford, UK)
D.E. Clark, Argenta Discovery Ltd. (Harlow, UK)
H. Köppen, Boehringer Ingelheim Pharma (Biberach, DE)
S. Knapp, University of Oxford (Oxford, UK)
O. Hvilsted Olsen, Novo Nordisk (Måløv, DK)
C. Kunick, Technische Universität Braunschweig (Braunschweig, DE)
Biopharmaceuticals
M. Glennie, University of Southampton (Southampton, UK)
K. Bosslet, MedImmune (Cambridge, UK)
A. Skerra, Technical University of Munich (Munich, DE)
P. Bäuerle, Micromet AG (Munich, DE)
G. Beste, Ablynx (Zwijnaarde, BE)
D. Neri, ETH (Zurich, CH)
SytemsX in MipTec
U. Sauer, Swiss Federal Institute of Technology (Zurich, CH)
N. Beerenwinkel, Swiss Federal Institute of Technology (Zurich, CH)
M. Zavolan, Biozentrum der Universität Basel (Basel, CH)